

# ANTICANCER RESEARCH

## International Journal of Cancer Research and Treatment

ISSN: 0250-7005

Volume 34, Number 1, January 2014

### Contents

#### Reviews

The Interaction Between DAP1 and Autophagy in the Context of Human Carcinogenesis. U. WAZIR, Z.S. KHANZADA, W.G. JIANG, A.K. SHARMA, A. KASEM, K. MOKBEL (*London; Cardiff, Wales, UK*) ..... 1

Nutrition and Pancreatic Cancer. M. PERICLEOUS, R.E. ROSSI, D. MANDAIR, T. WHYAND, M.E. CAPLIN (*London, UK; Milan, Italy*) ..... 9

The Key Role of *Bisphosphonates* in the Supportive Care of Cancer Patients. M. TOLIA, A. ZYGOIANNI, J.R. KOUVARIS, C. MERISTOUDIS, N. MARGARI, P. KARAKITSOS, I. KOKAKIS, D. KARDAMAKIS, C. PAPANIMITRIOU, K. MYSTAKIDOU, N. TSOUKALAS, G. KYRGIAS, B. ARMONIS, D.K. FILIPPIADIS, A.D. KELEKIS, N. KELEKIS, V. KOULOULIAS (*Athens; Patras; Larissa, Greece*) ..... 23

Counseling Patients on Cancer Diets: A Review of the Literature and Recommendations for Clinical Practice. J. HUEBNER, S. MARIENFELD, C. ABBENHARDT, C. ULRICH, K. MUENSTEDT, O. MICKE, R. MUECKE, C. LOESER (*Frankfurt am Main; Heidelberg; Gießen; Bielefeld; Bochum; Kassel, Germany*) ..... 39

#### Experimental Studies

Tumor-specific Localization of Self-assembled Nanoparticle PET/MR Modalities. I. HAJDU, G. TRENCSENYI, M. BODNÁR, M. EMRI, G. BÁNFALVI, J. SIKULA, T. MÁRIÁN, J. KOLLÁR, G. VÁMOSI, J. BORBÉLY (*Debrecen, Hungary*) ..... 49

Wilms' Tumor 1 Is Involved in Tumorigenicity of Glioblastoma by Regulating Cell Proliferation and Apoptosis. N. KIJIMA, N. HOSEN, N. KAGAWA, N. HASHIMOTO, M. KINOSHITA, Y. OJI, H. SUGIYAMA, T. YOSHIMINE (*Osaka, Japan*) ..... 61

*Contents continued on the back cover*

# ANTICANCER RESEARCH

International Journal of Cancer Research and Treatment



ISSN (print): 0250-7005  
ISSN (online): 1791-7530

## Editorial Board

**P.A. ABRAHAMSSON**, Malmö, Sweden  
**B. B. AGGARWAL**, Houston, TX, USA  
**T. AKIMOTO**, Kashiwa, Chiba, Japan  
**A. ARGIRIS**, San Antonio, TX, USA  
**J. P. ARMAND**, Toulouse, France  
**V. I. AVRAMIS**, Los Angeles, CA, USA  
**R. C. BAST**, Houston, TX, USA  
**G. BAUER**, Freiburg, Germany  
**E. E. BAULIEU**, Le Kremlin-Bicetre, France  
**Y. BECKER**, Jerusalem, Israel  
**E. J. BENZ, Jr.**, Boston, MA, USA  
**J. BERGH**, Stockholm, Sweden  
**D. D. BIGNER**, Durham, NC, USA  
**A. BÖCKING**, Düsseldorf, Germany  
**G. BONADONNA**, Milan, Italy  
**F. T. BOSMAN**, Lausanne, Switzerland  
**G. BROICH**, Monza, Italy  
**J. M. BROWN**, Stanford, CA, USA  
**Ø. S. BRULAND**, Oslo, Norway  
**M. M. BURGER**, Basel, Switzerland  
**M. CARBONE**, Honolulu, HI, USA  
**C. CARLBERG**, Kuopio, Finland  
**J. CARLSSON**, Uppsala, Sweden  
**A. F. CHAMBERS**, London, ON, Canada  
**P. CHANDRA**, Frankfurt am Main, Germany  
**L. CHENG**, Indianapolis, IN, USA  
**J.-G. CHUNG**, Taichung, Taiwan, ROC  
**E. DE CLERCQ**, Leuven, Belgium  
**W. DE LOECKER**, Leuven, Belgium  
**W. DEN OTTER**, Amsterdam, The Netherlands  
**E. P. DIAMANDIS**, Toronto, ON, Canada  
**G. TH. DIAMANDOPOULOS**, Boston, MA, USA  
**D. W. FELSHER**, Stanford, CA, USA  
**J. A. FERNANDEZ-POL**, Chesterfield, MO, USA  
**I. J. FIDLER**, Houston, TX, USA  
**A. P. FIELDS**, Jacksonville, FL, USA  
**B. FUCHS**, Zurich, Switzerland  
**G. GABBIANI**, Geneva, Switzerland  
**R. GANAPATHI**, Charlotte, NC, USA  
**A. F. GAZDAR**, Dallas, TX, USA  
**J. H. GESCHWIND**, Baltimore, MD, USA  
**A. GIORDANO**, Philadelphia, PA, USA  
**G. GITSCH**, Freiburg, Germany  
**R. H. GOLDFARB**, Saranac Lake, NY, USA  
**S. HAMMARSTRÖM**, Umeå, Sweden  
**I. HELLSTRÖM**, Seattle, WA, USA  
**L. HELSON**, Quakertown, PA, USA  
**R. M. HOFFMAN**, San Diego, CA, USA  
**K.-S. JEONG**, Daegu, South Korea  
**S. C. JHANWAR**, New York, NY, USA  
**J. V. JOHANNESSEN**, Oslo, Norway  
**B. KAINA**, Mainz, Germany  
**P. -I. KELLOKUMPU-LEHTINEN**, Tampere, Finland  
**B. K. KEPPLER**, Vienna, Austria  
**D. G. KIEBACK**, Riesa (Dresden), Germany  
**R. KLAPDOR**, Hamburg, Germany  
**U. R. KLEEBERG**, Hamburg, Germany  
**P. KLEIHUES**, Zürich, Switzerland  
**E. KLEIN**, Stockholm, Sweden  
**S. D. KOTTARIDIS**, Athens, Greece  
**G. R. F. KRUEGER**, Köln, Germany  
**D. W. KUFFE**, Boston, MA, USA  
**Pat M. KUMAR**, Manchester, UK  
**Shant KUMAR**, Manchester, UK  
**M. KUROKI**, Fukuoka, Japan  
**O. D. LAERUM**, Bergen, Norway  
**F. J. LEJEUNE**, Lausanne, Switzerland  
**L. F. LIU**, Piscataway, NJ, USA  
**D. M. LOPEZ**, Miami, FL, USA  
**E. LUNDGREN**, Umeå, Sweden  
**H. T. LYNCH**, Omaha, NE, USA  
**Y. MAEHARA**, Fukuoka, Japan  
**J. MAHER**, London, UK  
**J. MARESCAUX**, Strasbourg, France  
**J. MARK**, Skövde, Sweden  
**S. MITRA**, Houston, TX, USA  
**M. MUELLER**, Heidelberg, Germany  
**F. M. MUGGIA**, New York, NY, USA  
**M. J. MURPHY, Jr.**, Dayton, OH, USA  
**M. NAMIKI**, Kanazawa, Ishikawa, Japan  
**R. NARAYANAN**, Boca Raton, FL, USA  
**K. NILSSON**, Uppsala, Sweden  
**S. PATHAK**, Houston, TX, USA  
**J.L. PERSSON**, Malmö, Sweden  
**S. PESTKA**, Piscataway, NJ, USA  
**G. J. PILKINGTON**, Portsmouth, UK  
**C. D. PLATSOUKAS**, Norfolk, VA, USA  
**F. PODO**, Rome, Italy  
**A. POLLIACK**, Jerusalem, Israel  
**G. REBEL**, Strasbourg, France  
**M. RIGAUD**, Limoges, France  
**U. RINGBORG**, Stockholm, Sweden  
**M. ROSELLI**, Rome, Italy  
**A. SCHAUER**, Göttingen, Germany  
**M. SCHNEIDER**, Wuppertal, Germany  
**A. SETH**, Toronto, ON, Canada  
**G. V. SHERBET**, Newcastle-upon-Tyne, UK  
**G.-I. SOMA**, Tokushima, Japan  
**G. S. STEIN**, Burlington, VT, USA  
**T. STIGBRAND**, Umeå, Sweden  
**T. M. THEOPHANIDES**, Athens, Greece  
**B. TOTH**, Omaha, NE, USA  
**P. M. UELAND**, Bergen, Norway  
**H. VAN VLIERBERGHE**, Ghent, Belgium  
**P. T. VIHKO**, Oulu, Finland  
**R. G. VILE**, Rochester, MN, USA  
**M. WELLER**, Zurich, Switzerland  
**B. WESTERMARK**, Uppsala, Sweden  
**Y. YEN**, Duarte, CA, USA  
**M.R.I. YOUNG**, Charleston, SC, USA  
**B. ZUMOFF**, New York, NY, USA  
**J. G. DELINASIOS**, Athens, Greece  
Managing Editor  
**G. J. DELINASIOS**, Athens, Greece  
Assistant Managing Editor and  
Executive Publisher  
**E. ILIADIS**, Athens, Greece  
Production Editor

**Editorial Office:** International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki 19014, Greece. Tel / Fax: +30-22950-53389.

E-mails: Editorial Office: journals@iia-anticancer.org  
Managing Editor: editor@iia-anticancer.org

ANTICANCER RESEARCH supports: (a) the establishment and the activities of the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH (IIAR; Kapandriti, Attiki, Greece); and (b) the organization of the International Conferences of Anticancer Research.

For more information about ANTICANCER RESEARCH, IIAR and the Conferences, please visit the IIAR website: [www.iia-anticancer.org](http://www.iia-anticancer.org)

**Publication Data:** ANTICANCER RESEARCH (AR) is published monthly from January 2009. Each annual volume comprises 12 issues. Annual Author and Subject Indices are included in the last issue of each volume. ANTICANCER RESEARCH Vol. 24 (2004) and onwards appears online with Stanford University HighWire Press from April 2009.

**Copyright:** On publication of a manuscript in AR, which is a copyrighted publication, the legal ownership of all published parts of the paper passes from the Author(s) to the Journal.

**Annual Subscription Rates 2014 per volume:** Institutional subscription Euro 1,650.00 - print or online. Personal subscription Euro 780.00 - print or online. Prices include rapid delivery and insurance. The complete previous volumes of Anticancer Research (Vol. 1-33, 1981-2013) are available at 50% discount on the above rates.

**Subscription Orders:** Orders can be placed at agencies, bookstores, or directly with the Publisher. Cheques should be made payable to J.G. Delinasios, Executive Publisher of Anticancer Research, Athens, Greece, and should be sent to the Editorial Office.

**Advertising:** All correspondence and rate requests should be addressed to the Editorial Office.

**Book Reviews:** Recently published books and journals should be sent to the Editorial Office. Reviews will be published within 2-4 months.

Articles in ANTICANCER RESEARCH are regularly indexed in all bibliographic services, including Current Contents (Life Sciences), Science Citation Index, Index Medicus, Biological Abstracts, PubMed, Chemical Abstracts, Excerpta Medica, University of Sheffield Biomedical Information Service, Current Clinical Cancer, AIDS Abstracts, Elsevier Bibliographic Database, EMBASE, Compendex, GEOBASE, EMBiology, Elsevier BIOBASE, FLUIDEX, World Textiles, Scopus, Progress in Palliative Care, Cambridge Scientific Abstracts, Cancergram (International Cancer Research Data Bank), MEDLINE, Reference Update - RIS Inc., PASCAL-CNRS, Inpharma-Reactions (Datastar, BRS), CABS, Immunology Abstracts, Telegen Abstracts, Genetics Abstracts, Nutrition Research Newsletter, Dairy Science Abstracts, Current Titles in Dentistry, Inpharma Weekly, BioBase, MedBase, CAB Abstracts/Global Health Databases, Investigational Drugs Database, VINITI Abstracts Journal, Leeds Medical Information, PubsHub, Sociedad Iberoamericana de Información Científica (SIIC) Data Bases.

Authorization to photocopy items for internal or personal use, or the internal or personal clients, is granted by ANTICANCER RESEARCH, provided that the base fee of \$2.00 per copy, plus 0.40 per page is paid directly to the Copyright Clearance Center, 27 Congress Street, Salem, MA 01970, USA. For those organizations that have been granted a photocopy license by CCC, a separate system of payment has been arranged. The fee code for users of the Transactional Reporting Service is 0250-7005/2014 \$2.00 +0.40.

The Editors and Publishers of ANTICANCER RESEARCH accept no responsibility for the opinions expressed by the contributors or for the content of advertisements appearing therein.

Copyright© 2014, International Institute of Anticancer Research  
(Dr. John G. Delinasios), All rights reserved.  
D.T.P. BY IIAR  
PRINTED BY ENTYP0, ATHENS, GREECE  
PRINTED ON ACID-FREE PAPER

# ANTICANCER RESEARCH

International Journal of Cancer Research and Treatment  
ISSN (print): 0250-7005, ISSN (online): 1791-7530

VOLUME 34  
2014

## Editorial Board

<b>P.A. Abrahamsson</b>	Department of Urology, Skåne University Hospital, Lund University, Malmö, Sweden
<b>B. B. Aggarwal</b>	Cytokine Research Laboratory, Department of Experimental Therapeutics, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
<b>T. Akimoto</b>	Division of Partical Therapy and Department of Radiation Oncology, National Cancer Center East, Kashiwa, Chiba, Japan
<b>A. Argiris</b>	Division of Hematology/Oncology, UT Health Science Center at San Antonio, San Antonio, TX, USA
<b>J. P. Armand</b>	Institut Claudius Regaud, Toulouse, France
<b>V. I. Avramis</b>	Division of Hematology/Oncology, Childrens Hospital, Los Angeles, CA, USA
<b>R. C. Bast</b>	Department of Translational Research, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
<b>G. Bauer</b>	Abteilung Virologie, Institut für Medizinische Mikrobiologie und Hygiene, Universität Freiburg, Germany
<b>E. E. Baulieu</b>	INSERM U488 and College de France, Le Kremlin-Bicetre, France
<b>Y. Becker</b>	Department of Biochemistry, Faculty of Medicine, Hebrew University of Jerusalem, Ein Kerem, Jerusalem, Israel
<b>E. J. Benz, Jr.</b>	Dana-Farber Cancer Institute, Boston, MA, USA
<b>J. Bergh</b>	Department of Clinical and Molecular Medicine, Radiumhemmet, Karolinska Institute, Stockholm, Sweden
<b>D. D. Bigner</b>	Department of Pathology, Duke University Medical Center, Durham, NC, USA
<b>A. Böcking</b>	Institute for Cytopathology, University of Düsseldorf, Germany
<b>G. Bonadonna</b>	Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano, Italy
<b>F. T. Bosman</b>	Institute of Pathology, University of Lausanne, Switzerland
<b>G. Broich</b>	Gruppo Policlinico di Monza, Monza, Italy
<b>J. M. Brown</b>	Department of Radiation Oncology, Stanford Medical Center, Stanford, CA, USA
<b>Ø. S. Bruland</b>	Department of Medical Oncology-Radiotherapy, Norwegian Radium Hospital, Oslo, Norway
<b>M. M. Burger</b>	Novartis, Basel, Switzerland
<b>M. Carbone</b>	Cancer Research Center of Hawaii, Honolulu, HI, USA
<b>C. Carlberg</b>	Institute of Biomedicine, University of Eastern Finland, Kuopio, Finland
<b>J. Carlsson</b>	Department of Biomedical Radiation Sciences, Uppsala University, Sweden
<b>A. F. Chambers</b>	Department of Oncology, London Regional Cancer Center, London, Ontario, Canada
<b>P. Chandra</b>	Abt. für Molekularbiologie, Klinikum Wolfgang Goethe-Universität, Frankfurt am Main, Germany
<b>L. Cheng</b>	Department of Pathology, Indiana University School of Medicine, Indianapolis, IN, USA
<b>J.-G. Chung</b>	Department of Biological Science and Technology, China Medical University, Taichung, Taiwan, ROC
<b>E. De Clercq</b>	Rega Institute for Medical Research, Katholieke Universiteit Leuven, Belgium
<b>W. De Loecker</b>	Department of Biochemistry, Katholieke Universiteit Leuven, Belgium
<b>W. Den Otter</b>	VUMC, Department of Urology, Amsterdam, The Netherlands
<b>E. P. Diamandis</b>	Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada
<b>G. Th. Diamandopoulos</b>	Department of Pathology, Harvard Medical School, Boston, MA, USA
<b>D.W. Felsher</b>	Division of Oncology, Stanford University School of Medicine, Stanford, CA, USA
<b>J. A. Fernandez-Pol</b>	Metalloproteomics, LLC, Chesterfield, MO, USA
<b>I. J. Fidler</b>	Department of Cancer Biology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
<b>A.P. Fields</b>	Department of Cancer Biology, College of Medicine, Mayo Clinic, Jacksonville, FL, USA
<b>B. Fuchs</b>	Balgrist University Hospital, Zurich, Switzerland
<b>G. Gabbiani</b>	Department of Pathology, University of Geneva, Switzerland
<b>R. Ganapathi</b>	Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC, USA
<b>A. F. Gazdar</b>	Hamon Center for Therapeutic Oncology Research, University of Texas Southeastern Medical Center, Dallas, TX, USA
<b>J.H. Geschwind</b>	Interventional Radiology Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA
<b>A. Giordano</b>	Sbarro Institute for Cancer Research, Temple University, Philadelphia, PA, USA
<b>G. Gitsch</b>	Department of Gynecology and Obstetrics, University of Freiburg, Germany
<b>R. H. Goldfarb</b>	Trudeau Institute, Saranac Lake, NY, USA

- S. Hammarström** Department of Immunology, University of Umeå, Sweden
- I. Hellström** Harborview Medical Center, Seattle, WA, USA
- L. Helson** Sign Path Pharma, Inc., Quakertown, PA, USA
- R. M. Hoffman** Department of Surgery, University of California, San Diego, CA, USA
- K.-S. Jeong** Department of Pathology, College of Veterinary Medicine, Kyungpook National University, Daegu, South Korea
- S. C. Jhanwar** Laboratory of Solid Tumor Genetics, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
- J. V. Johannessen** Department of Pathology, The Norwegian Radium Hospital, Oslo, Norway
- B. Kaina** Institute of Toxicology, University of Mainz, Germany
- P. -L. Kellokumpu-Lehtinen** Department of Oncology and Radiotherapy, Tampere University Hospital, Tampere, Finland
- B. K. Keppler** School of Medicine, University of Vienna, Austria
- D. G. Kieback** Department of Obstetrics and Gynecology, Elblandklinikum Riesa, Riesa (Dresden), Germany
- R. Klapdor** Medical Clinic, University of Hamburg, Germany
- U. R. Kleeberg** Hämatologisch - Onkologisch - Praxis Altona, Hamburg, Germany
- P. Kleihues** Department of Pathology, University Hospital Zürich, Switzerland
- E. Klein** Department of Tumor Biology, Karolinska Institute, Stockholm, Sweden
- S. D. Kottaridis** Department of Virology, Hellenic Anticancer Institute, Athens, Greece
- G. R. F. Krueger** Center of Anatomy II, University of Cologne Medical School, Cologne, Germany
- D. W. Kufe** Division of Medicine, Dana-Farber Cancer Institute, Boston, MA, USA
- Pat M. Kumar** Department of Biological Sciences, Manchester Metropolitan University, Manchester, UK
- Shant Kumar** Department Pathology, University of Manchester Medical School, Manchester, UK
- M. Kuroki** Department of Biochemistry, Fukuoka University School of Medicine, Fukuoka, Japan
- O. D. Laerum** Department of Pathology, The Gade Institute, University of Bergen, Norway
- F. J. Lejeune** Fondation du Centre Pluridisciplinaire d' Oncologie, CHUV, Lausanne, Switzerland
- L. F. Liu** Department of Pharmacology, UMD of New Jersey, Piscataway, NJ, USA
- D. M. Lopez** Department of Microbiology and Immunology, University of Miami School of Medicine, Miami, FL, USA
- E. Lundgren** Unit of Applied Cell and Molecular Biology, University of Umeå, Sweden
- H. T. Lynch** Department of Preventive Medicine and Public Health, Creighton University, Omaha, NE, USA
- Y. Maehara** Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
- J. Maher** Department of Research Oncology, Division of Cancer Studies, King's College London School of Medicine, Guy's Hospital Campus, London, UK
- J. Marescaux** IRCAD, University of Strasbourg, France
- J. Mark** Department of Pathology, Kärnshjukhuset, Skövde, Sweden
- S. Mitra** The Methodist Hospital Research Institute (TMHRI), Houston, TX, USA
- M. Mueller** Research Group of Tumor and Microenvironment (A101), German Cancer Research Center (DKFZ), Heidelberg, Germany
- F. M. Muggia** New York University Cancer Institute, School of Medicine, NY, USA
- M. J. Murphy, Jr.** Hipple Cancer Research Center, Dayton, OH, USA
- M. Namiki** Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa City, Ishikawa, Japan
- R. Narayanan** Department of Biological Sciences, Florida Atlantic University, Boca Raton, FL, USA
- K. Nilsson** Rudbeck Laboratory, Department of Genetics and Pathology, Uppsala University Hospital, Sweden
- S. Pathak** Department of Cell Biology, University of Texas, Houston, TX, USA
- J.L. Persson** Section for Experimental Cancer Research, Clinical Research Center, Lund University, Malmö, Sweden
- S. Pestka** Department of Molecular Genetics and Microbiology, University of Medicine and Dentistry of New Jersey, Piscataway, NJ, USA
- G. J. Pilkington** Department of Cellular and Molecules Neurooncology, School of Pharmacy and Biomedical Sciences, University of Portsmouth, UK
- C. D. Platsoucas** College of Sciences, Old Dominion University, Norfolk, VA, USA

<b>F. Podo</b>	Laboratory of Cell Biology, Istituto Superiore di Sanità, Rome, Italy
<b>A. Polliack</b>	Department of Haematology, Hadassah University Hospital and Medical School, Jerusalem, Israel
<b>G. Rebel</b>	IRCAD, Hopitaux Universitaires, Strasbourg, France
<b>M. Rigaud</b>	Laboratory Biochimie et Génétique Molécules, Faculté de Médecine de Limoges, France
<b>U. Ringborg</b>	Department of General Oncology, Karolinska Hospital, Stockholm, Sweden
<b>M. Roselli</b>	Department of Medical Oncology, University of Rome "Tor Vergata", Italy
<b>A. Schauer</b>	Zentrum Pathologie, Georg-August Universität, Göttingen, Germany
<b>M. Schneider</b>	Department of Organic Chemistry, Bergische University, Wuppertal, Germany
<b>A. Seth</b>	Laboratory of Molecular Pathology, Sunnybrook Research Institute and University of Toronto, Ontario, Canada
<b>G. V. Sherbet</b>	Cancer Research Unit, University of Newcastle-upon-Tyne, UK
<b>G.-I. Soma</b>	Institute for Health Sciences, Tokushima Bunri University, Tokushima, Japan
<b>G. S. Stein</b>	Department of Biochemistry, College of Medicine, University of Vermont, Burlington, VT, USA
<b>T. Stigbrand</b>	Department of Immunology, Umeå University, Umeå, Sweden
<b>T. M. Theophanides</b>	Department of Chemistry, Technical University of Athens, Greece
<b>B. Toth</b>	The Eppley Institute for Research in Cancer and Allied Diseases, Omaha, NE, USA
<b>P. M. Ueland</b>	Clinical Pharmacology Unit, Department of Pharmacology, University of Bergen, Norway
<b>H. Van Vlierberghe</b>	Department of Gastroenterology and Hepatology, Ghent University Hospital, Ghent, Belgium
<b>R.G. Vile</b>	Department of Immunology, Mayo Clinic, Rochester, MN, USA
<b>M. Weller</b>	Department of Neurology, University Hospital Zurich, Zurich, Switzerland
<b>B. Westermark</b>	Rudbecklaboratoriet, Department of Genetics and Pathology, University of Uppsala, Sweden
<b>Y. Yen</b>	Department of Molecular Pharmacology, City of Hope, Duarte, CA, USA
<b>M.R.I. Young</b>	Ralph H. Johnson VA Medical Center, Medical University of South Carolina, Charleston, SC, USA
<b>B. Zumoff</b>	Division of Endocrinology and Metabolism, Beth Israel Medical Center, New York, NY, USA



## Instructions to Authors 2014

*General Policy.* ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide prompt publication (print and online) for original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works on the cancer problem that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

*NIH Open Access Policy.* The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

*Copyright.* Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has been transferred from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without the written consent of the Managing Editor or Publisher.

*Format.* Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the "Shorter Oxford English Dictionary".

*Manuscripts.* Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections:

(a) *First page* including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication "review", "clinical", "epidemiological", or "experimental" study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) *Abstract* not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) *Introduction*; (d) *Materials and Methods/Patients and Methods*; (e) *Results*; (f) *Discussion*; (g) *Acknowledgements*; (h) *References*. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

*Figures.* All figures (whether photographs or graphs) should be clear, high contrast, at the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Colour plates are charged.

*Tables.* Tables should be typed double-spaced on a separate page, numbered with Roman numerals and should include a short title.

*References.* Authors must assume responsibility for the accuracy of the references used. Citations for the reference sections of submitted works should follow the standard form of "Index Medicus" and must be numbered consecutively. In the text, references should be cited by number. Examples: 1 Sumner AT: The nature of chromosome bands and their significance for cancer research. *Anticancer Res* 1: 205-216, 1981. 2 McGuire WL and Chamnes GC: Studies on the oestrogen receptor in breast cancer. In: *Receptors for Reproductive Hormones* (O' Malley BW, Chamnes GC (eds.). New York, Plenum Publ Corp., pp 113-136, 1973.

*Nomenclature and Abbreviations.* Nomenclature should follow that given in "Chemical Abstracts", "Index Medicus", "Merck Index", "IUPAC –IUB", "Bergey's Manual of Determinative Bacteriology", The CBE Manual for Authors, Editors and Publishers (6th edition, 1994), and MIAME Standard for Microarray Data. Human gene symbols may be obtained from the HUGO Gene Nomenclature Committee (HGNC) (<http://www.gene.ucl.ac.uk/>). Approved mouse nomenclature may be obtained from <http://www.informatics.jax.org/>. Standard abbreviations are preferable. If a new abbreviation is used, it must be defined on first usage.

*Clinical Trials.* Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by "ISRCTN"). Please note that there is no space between the prefix "ISRCTN" and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by 'NCT'). Please note that there is no space between the prefix 'NCT' and the number. Example: NCT00001789.

*Ethical Policies and Standards.* ANTICANCER RESEARCH agrees with and follows the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 ([www.icmje.org](http://www.icmje.org)). Microarray data analysis should comply with the "Minimum Information About Microarray Experiments (MIAME) standard". Specific guidelines are provided at the "Microarray Gene Expression Data Society" (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

*Submission of Manuscripts.* Please follow the Instructions to Authors regarding the format of your manuscript and references. There are 3 ways to submit your article (NOTE: Please use only one of the 3 options. Do not send your article twice.):

1. To submit your article online please visit: IIAR-Submissions (<http://www.iiar-anticancer.org/submissions/login.php>)
2. You can send your article via e-mail to [journals@iiar-anticancer.org](mailto:journals@iiar-anticancer.org). Please remember to always indicate the name of the journal you wish to submit your paper. The text should be sent as a Word document (\*.doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments.
3. You can send the manuscript of your article via regular mail in a USB stick, DVD, CD or floppy disk (including text, tables and figures) together with three hard copies to the following address:

John G. Delinasios  
International Institute of Anticancer Research (IIAR)  
Editorial Office of ANTICANCER RESEARCH,  
IN VIVO, CANCER GENOMICS and PROTEOMICS.  
1st km Kapandritiou-Kalamou Road  
P.O. Box 22, GR-19014 Kapandriti, Attiki  
GREECE

Submitted articles will not be returned to Authors upon rejection.

*Galley Proofs.* Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance of the paper. Requests should be addressed to the Editorial Office.

Copyright© 2014 - International Institute of Anticancer Research (J.G. Delinasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.



## Reviews